Presentation TVT 2014 The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies Presenter: David J. Cohen June 07, 2014
Presentation Fellows 2014 Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist Presenter: David Cohen April 12, 2014
News Daily News Apixaban es Rentable comparado con Warfarina o Aspirina Caitlin E. Cox February 26, 2014
News Daily News Apixaban Cost-Effective Compared with Warfarin or Aspirin Caitlin E. Cox February 26, 2014
News Daily News For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs July 25, 2013
News Daily News En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida July 25, 2013
Presentation TCT 2012 A Stepwise Approach to Building a Career in Interventional Cardiology Research Presenter: David Cohen October 25, 2012
Presentation TCT 2012 An Introduction to Cost-Effectiveness Analyses: Who Pays (and Should They)? Presenter: David Cohen October 22, 2012
News Daily News Un Modelo Sugiere que la Denervación Renal es Rentable contra la Hipertensión Resistente September 13, 2012
News Daily News Model Suggests Renal Denervation Cost-effective for Resistant Hypertension September 13, 2012
News Daily News Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years Caitlin E. Cox July 12, 2012
News Daily News A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA Caitlin E. Cox July 12, 2012
News Daily News Reducir el Uso de SLF a la Mitad en Pacientes de Bajo Riesgo podría suponer un Ahorro de 200 millones de Dólares al Año Yael L. Maxwell July 11, 2012
News Daily News Halving DES Use in Low-Risk Patients Could Save $200 Million Annually Yael L. Maxwell July 11, 2012
News Daily News Las Complicaciones Operatorias No son las Culpables de la Muerte tras una PCI March 06, 2012
News Daily News DES Add Over $1.5 Billion in Medicare Costs to Health Care System Jason Kahn April 28, 2011